MOTS-c vs Amylin

MOTS-c and Amylin are both research peptides studied across multiple applications, but they operate through fundamentally different biological pathways. MOTS-c is a mitochondrial-derived peptide that acts as a metabolic regulator, primarily via AMPK activation, and has shown promise in preclinical models for improving insulin sensitivity and exercise capacity. Amylin, on the other hand, is an endogenous pancreatic hormone co-secreted with insulin that regulates postprandial glucose by slowing gastric emptying and suppressing glucagon. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.

Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.

Amylin (islet amyloid polypeptide, IAPP) is an endogenous 37-amino-acid peptide hormone (MW ~3903.3 g/mol) co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. It plays a key role in postprandial glucose regulation by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety. Amylin is deficient in type 1 diabetes and relatively deficient in advanced type 2 diabetes. While amylin itself is not used as a drug due to its propensity to form amyloid fibrils, it is the basis for the approved analog pramlintide (Symlin) and the investigational long-acting analog cagrilintide. Key claims include its co-secretion with insulin and deficiency in diabetes, slowing gastric emptying, and suppressing postprandial glucagon secretion. The evidence for amylin's physiological role is robust, with decades of research and clinical validation through its analogs.

Both peptides are studied for metabolic health, but their specific research contexts differ. MOTS-c is primarily investigated for its potential in anti-aging and exercise mimetic applications, with a focus on improving insulin sensitivity and combating age-related metabolic decline. Amylin research centers on postprandial glucose regulation and satiety, with applications in diabetes and obesity. While both target metabolic pathways, MOTS-c's research is more exploratory and preclinical, whereas Amylin's role is well-established with clinical analogs. Researchers should consider these distinctions when designing studies: MOTS-c may be more suitable for aging or exercise-related metabolic research, while Amylin is ideal for glucose homeostasis and appetite regulation studies.

For MOTS-c, no adverse effects have been reported in preclinical animal studies, but human tolerability is completely unknown for native MOTS-c as no completed human trials exist. The modified analog CB4211 showed good tolerability in Phase 1, but this does not directly apply to the native peptide. For Amylin, as an endogenous hormone, it is not administered therapeutically due to its propensity to aggregate into amyloid fibrils at physiological concentrations, making it unsuitable as a drug. These amyloid aggregates are cytotoxic to beta cells and contribute to disease progression in type 2 diabetes. Researchers should weigh the unknown human safety profile of MOTS-c against the well-documented aggregation risk of native Amylin, and consider using analogs like pramlintide for translational studies.